JP2024524301A5 - - Google Patents
Info
- Publication number
- JP2024524301A5 JP2024524301A5 JP2023579541A JP2023579541A JP2024524301A5 JP 2024524301 A5 JP2024524301 A5 JP 2024524301A5 JP 2023579541 A JP2023579541 A JP 2023579541A JP 2023579541 A JP2023579541 A JP 2023579541A JP 2024524301 A5 JP2024524301 A5 JP 2024524301A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- optionally
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/104201 | 2021-07-02 | ||
| CN2021104201 | 2021-07-02 | ||
| PCT/CN2022/102692 WO2023274352A1 (en) | 2021-07-02 | 2022-06-30 | Depletion of activated hepatic stellate cells (hscs) and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524301A JP2024524301A (ja) | 2024-07-05 |
| JP2024524301A5 true JP2024524301A5 (enExample) | 2025-07-07 |
Family
ID=84691485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579541A Pending JP2024524301A (ja) | 2021-07-02 | 2022-06-30 | 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240254239A1 (enExample) |
| EP (1) | EP4363443A4 (enExample) |
| JP (1) | JP2024524301A (enExample) |
| KR (1) | KR20240070496A (enExample) |
| CN (2) | CN119039440A (enExample) |
| AU (1) | AU2022304943A1 (enExample) |
| CA (1) | CA3222788A1 (enExample) |
| IL (1) | IL309804A (enExample) |
| MX (1) | MX2024000057A (enExample) |
| TW (1) | TW202317632A (enExample) |
| WO (1) | WO2023274352A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115443150A (zh) | 2019-12-17 | 2022-12-06 | 德克萨斯大学系统董事会 | 新型ddr1抗体和其用途 |
| CN116492463B (zh) * | 2023-03-31 | 2023-11-17 | 珠海市人民医院 | Cd155分子在肝纤维化领域中的应用 |
| WO2025026353A1 (en) * | 2023-08-01 | 2025-02-06 | Laekna Therapeutics Shanghai Co., Ltd. | Anti-acvr2b antibodies and uses thereof |
| CN119930817B (zh) * | 2024-12-24 | 2025-12-02 | 国科大杭州高等研究院 | Tigit全人源抗体及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2011265460B2 (en) * | 2003-01-09 | 2014-07-17 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2012261721A1 (en) * | 2006-03-17 | 2013-01-10 | Gilead Sciences, Inc. | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists |
| EP2673297A2 (en) * | 2011-02-11 | 2013-12-18 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| CN104628866B (zh) * | 2015-01-21 | 2018-03-27 | 中国药科大学 | 一种靶向vegfr2的抗体融合蛋白的制备及其用途 |
| CN104592395B (zh) * | 2015-01-27 | 2017-11-14 | 中国药科大学 | Vegfr2单链抗体与mica融合蛋白的制备方法及用途 |
| EP3397645B1 (en) * | 2015-12-28 | 2026-03-25 | Innate Pharma | Variable regions for nkp46 binding proteins |
| IL317989A (en) * | 2016-08-17 | 2025-02-01 | Compugen Ltd | Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof |
| CN111836831A (zh) * | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药 |
| GB201809700D0 (en) * | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| JP2022532430A (ja) * | 2019-05-16 | 2022-07-14 | シャタック ラボ，インコーポレイテッド | Ｎｋ細胞指向性キメラタンパク質 |
-
2022
- 2022-06-30 JP JP2023579541A patent/JP2024524301A/ja active Pending
- 2022-06-30 IL IL309804A patent/IL309804A/en unknown
- 2022-06-30 EP EP22832164.2A patent/EP4363443A4/en active Pending
- 2022-06-30 CN CN202411176778.8A patent/CN119039440A/zh active Pending
- 2022-06-30 AU AU2022304943A patent/AU2022304943A1/en active Pending
- 2022-06-30 MX MX2024000057A patent/MX2024000057A/es unknown
- 2022-06-30 CA CA3222788A patent/CA3222788A1/en active Pending
- 2022-06-30 KR KR1020247000140A patent/KR20240070496A/ko active Pending
- 2022-06-30 WO PCT/CN2022/102692 patent/WO2023274352A1/en not_active Ceased
- 2022-06-30 US US18/574,243 patent/US20240254239A1/en active Pending
- 2022-06-30 CN CN202280057249.9A patent/CN117980328A/zh active Pending
- 2022-06-30 TW TW111124547A patent/TW202317632A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| JP2024524301A5 (enExample) | ||
| JP7132232B2 (ja) | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 | |
| US20220226469A1 (en) | Therapeutic sirp-alpha antibodies | |
| EP3265575B1 (en) | Cd20 binding molecules and uses thereof | |
| US20240150464A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| US20160137740A1 (en) | Humanized anti-ox40 antibodies and uses thereof | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2022547081A (ja) | 抗ｃｄ７３抗体 | |
| JP2019500892A5 (enExample) | ||
| JP2015533853A5 (enExample) | ||
| JP2018524326A (ja) | 多重特異的ｎｋエンゲイジャータンパク質 | |
| JP2020529835A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2018528776A5 (enExample) | ||
| CN106029694A (zh) | 治疗性肽 | |
| JP2022542559A5 (enExample) | ||
| JP2020511481A (ja) | 固形及び血液癌の治療のための併用療法 | |
| JP2023524238A (ja) | 治療用ＳＩＲＰα抗体 | |
| JP2024526324A5 (enExample) | ||
| JP2023545183A5 (enExample) | ||
| CN114901364A (zh) | 用于治疗实体癌和血液癌的组合疗法 | |
| JP2021512652A5 (enExample) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2021505637A (ja) | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |